{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T03:11:50Z","timestamp":1787195510234,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001202","name":"Gastroenterological Society of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023921","name":"Structural Genomics Consortium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejmech.2026.118838","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T01:02:21Z","timestamp":1775437341000},"page":"118838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discovery of APO-50815, a potent WEE1 kinase inhibitor with exceptional efficacy against patient-derived colorectal cancer organoids"],"prefix":"10.1016","volume":"312","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7139-3863","authenticated-orcid":false,"given":"Joel L.","family":"Syphers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4588-8827","authenticated-orcid":false,"given":"Josephine A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah","family":"de Nys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharindie N.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vrbanac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate R.","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Leeflang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia T.","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie F.","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2707-6270","authenticated-orcid":false,"given":"Yi Sing","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0769-516X","authenticated-orcid":false,"given":"Aeson","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-4231","authenticated-orcid":false,"given":"Savannah","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2355-1433","authenticated-orcid":false,"given":"Erica K.","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Worthley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-4699","authenticated-orcid":false,"given":"Siddhartha","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4477-5807","authenticated-orcid":false,"given":"Kieran","family":"Stockton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7840-0405","authenticated-orcid":false,"given":"Daniel L.","family":"Priebbenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2114-8242","authenticated-orcid":false,"given":"Jonathan B.","family":"Baell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejmech.2026.118838_bib1","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/s41418-023-01196-z","article-title":"Cyclers' kinases in cell division: from molecules to cancer therapy","volume":"30","author":"Milletti","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2026.118838_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110310","article-title":"The expanding role of WEE1","volume":"94","author":"Koh","year":"2022","journal-title":"Cell. Signal."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118838_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"19","key":"10.1016\/j.ejmech.2026.118838_bib4","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.4161\/cc.26062","article-title":"Wee1 kinase as a target for cancer therapy","volume":"12","author":"Do","year":"2013","journal-title":"Cell Cycle"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118838_bib5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1358\/dnp.2010.23.7.1490760","article-title":"Targeting Wee1-like protein kinase to treat cancer","volume":"23","author":"Stathis","year":"2010","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.ejmech.2026.118838_bib6","series-title":"Evolutionary Dynamics of Malignancy: the Genetic and Environmental Causes of Cancer","first-page":"65","article-title":"The DNA damage checkpoint","author":"Jackson","year":"2023"},{"key":"10.1016\/j.ejmech.2026.118838_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/jpp\/rgae060","article-title":"GL-V9 synergizes with oxaliplatin of colorectal cancer via Wee1 degradation mediated by HSP90 inhibition","author":"Chen","year":"2024","journal-title":"J. Pharm. Pharmacol."},{"issue":"20","key":"10.1016\/j.ejmech.2026.118838_bib8","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1128\/MCB.00412-12","article-title":"Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption","volume":"32","author":"Beck","year":"2012","journal-title":"Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118838_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110261","article-title":"WEE1 kinase protects the stability of stalled DNA replication forks by limiting CDK2 activity","volume":"38","author":"Elb\u00e6k","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.118838_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102531","article-title":"Clinical development of WEE1 inhibitors in gynecological cancers: a systematic review","volume":"115","author":"Schutte","year":"2023","journal-title":"Cancer Treat Rev."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118838_bib11","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1158\/1535-7163.MCT-09-0463","article-title":"Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents","volume":"8","author":"Hirai","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"issue":"6810","key":"10.1016\/j.ejmech.2026.118838_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"issue":"03.13","key":"10.1016\/j.ejmech.2026.118838_bib13","article-title":"Exploiting WEE1 kinase activity as FUS::DDIT3-dependent therapeutic vulnerability in myxoid liposarcoma","volume":"2024","author":"Heinst","year":"2024","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118838_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118838_bib15","article-title":"Wee1 inhibitor AZD1775 combined with Cisplatin potentiates anticancer activity against gastric cancer by increasing DNA damage and cell apoptosis","volume":"2018","author":"Chen","year":"2018","journal-title":"BioMed Res. Int."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118838_bib16","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1021\/acschembio.6b00466","article-title":"A WEE1 inhibitor analog of AZD1775 maintains synergy with Cisplatin and demonstrates reduced single-agent cytotoxicity in medulloblastoma cells","volume":"11","author":"Matheson","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"16","key":"10.1016\/j.ejmech.2026.118838_bib17","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/cmdc.201800188","article-title":"Development of potent Pyrazolopyrimidinone-Based WEE1 inhibitors with limited single-agent cytotoxicity for cancer therapy","volume":"13","author":"Matheson","year":"2018","journal-title":"ChemMedChem"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118838_bib18","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1021\/acschembio.7b00147","article-title":"Dual targeting of WEE1 and PLK1 by AZD1775 elicits single agent cellular anticancer activity","volume":"12","author":"Wright","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118838_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104233","article-title":"Adavosertib and beyond: biomarkers, drug combination and toxicity of WEE1 inhibitors","volume":"193","author":"Zhang","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118838_bib20","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1097\/MS9.0000000000003373","article-title":"PLK1 inhibitors for the treatment of colorectal cancer","volume":"87","author":"Ye","year":"2025","journal-title":"Ann. Med. Surg."},{"issue":"23","key":"10.1016\/j.ejmech.2026.118838_bib21","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-20-2586","article-title":"A phase Ib study of Onvansertib, a novel oral PLK1 inhibitor, in combination therapy for patients with relapsed or refractory acute Myeloid leukemia","volume":"26","author":"Zeidan","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118838_bib22","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-10-2946","article-title":"Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies","volume":"17","author":"Olmos","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118838_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2011.11.001","article-title":"A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours","volume":"48","author":"Sch\u00f6ffski","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118838_bib24","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1021\/acsmedchemlett.2c00481","article-title":"Selective Wee1 inhibitors led to antitumor activity in vitro and correlated with myelosuppression","volume":"14","author":"Guler","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"33","key":"10.1016\/j.ejmech.2026.118838_bib25","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.21.01435","article-title":"Inhibition of WEE1 is effective in TP53- and RAS-Mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring","volume":"39","author":"Seligmann","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ejmech.2026.118838_bib26","doi-asserted-by":"crossref","first-page":"13004","DOI":"10.1021\/acs.jmedchem.1c01121","article-title":"Discovery of ZN-c3, a highly potent and selective Wee1 inhibitor undergoing evaluation in clinical trials for the treatment of cancer","volume":"64","author":"Huang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118838_bib27","unstructured":"Azenosertib clinical trials pipeline. https:\/\/www.zentalis.com\/pipeline\/pipeline#azenosertib (accessed December 22, 2025)."},{"key":"10.1016\/j.ejmech.2026.118838_bib28","series-title":"Open-Label, Multi-Center Study of ZN-c3 Administered in Combination with Encorafenib and Cetuximab in Adults with Metastatic Colorectal Cancer. in Pfizer, Ed","year":"2023"},{"issue":"23","key":"10.1016\/j.ejmech.2026.118838_bib29","doi-asserted-by":"crossref","first-page":"20196","DOI":"10.1021\/acsomega.3c01558","article-title":"Synthetic and medicinal chemistry approaches toward WEE1 kinase inhibitors and its degraders","volume":"8","author":"Alli","year":"2023","journal-title":"ACS Omega"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118838_bib30","doi-asserted-by":"crossref","first-page":"8065","DOI":"10.1021\/acs.jmedchem.4c02541","article-title":"Discovery of WEE1 kinase inhibitors with potent activity against patient-derived, metastatic colorectal cancer organoids","volume":"68","author":"Syphers","year":"2025","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118838_bib31","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/jcc.540150503","article-title":"ICM\u2014A new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation","volume":"15","author":"Abagyan","year":"1994","journal-title":"J. Comput. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118838_bib32","doi-asserted-by":"crossref","first-page":"9927","DOI":"10.1021\/acs.jmedchem.3c02434","article-title":"Advanced design, synthesis, and evaluation of highly selective Wee1 inhibitors: enhancing pharmacokinetics and antitumor efficacy","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2026.118838_bib33","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1158\/1078-0432.CCR-20-0073","article-title":"Medium-throughput drug screening of patient-derived organoids from colorectal peritoneal metastases to direct personalized therapy","volume":"26","author":"Narasimhan","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118838_bib34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3393\/ac.2021.00920.0131","article-title":"Treatment for peritoneal metastasis of patients with colorectal cancer","volume":"37","author":"Kim","year":"2021","journal-title":"Ann. Coloproctol"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118838_bib35","article-title":"Colorectal liver metastasis: molecular mechanism and interventional therapy","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"6444","key":"10.1016\/j.ejmech.2026.118838_bib36","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1126\/science.aaw6985","article-title":"Cancer modeling meets human organoid technology","volume":"364","author":"Tuveson","year":"2019","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.ejmech.2026.118838_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153701","article-title":"Cancer organoids in basic science and translational medicine","volume":"13","author":"Memeo","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118838_bib38","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/gutjnl-2017-315920","article-title":"Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis","volume":"68","author":"Lannagan","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2026.118838_bib39","article-title":"Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges","author":"Wang","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118838_bib40","series-title":"FDA Announces Plan to Phase out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs","author":"Food","year":"2025"},{"issue":"18","key":"10.1016\/j.ejmech.2026.118838_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16183136","article-title":"WEE1 inhibitor adavosertib exerts antitumor effects on colorectal cancer, especially in cases with p53 mutations","volume":"16","author":"Ariyoshi","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.118838_bib42","series-title":"Selective Macrocyclic WEE1 Kinase Inhibitors with Strong Efficacy Against Patient-Derived Colorectal Cancer Organoids. Manuscript in Preparation","author":"Syphers","year":"2026"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118838_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"30","key":"10.1016\/j.ejmech.2026.118838_bib44","doi-asserted-by":"crossref","first-page":"E6231","DOI":"10.1073\/pnas.1701848114","article-title":"Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery","volume":"114","author":"Mateus","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2026.118838_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116663","article-title":"H2AX: a key player in DNA damage response and a promising target for cancer therapy","volume":"175","author":"Prabhu","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118838_bib46","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118838_bib47","article-title":"Functional and genomic characterisation of a xenograft model system for the study of metastasis in triple-negative breast cancer","volume":"11","author":"Johnstone","year":"2018","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ejmech.2026.118838_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1298245","article-title":"Discovery of potential WEE1 inhibitors via hybrid virtual screening","volume":"14","author":"Jin","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118838_bib49","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1172\/JCI122622","article-title":"Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis","volume":"129","author":"Bukhari","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.118838_bib50","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-1-61779-337-0_7","article-title":"Kinase inhibitor selectivity profiling using differential scanning fluorimetry","volume":"795","author":"Fedorov","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118838_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112770","article-title":"Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor","volume":"208","author":"Kr\u00e4mer","year":"2020","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:29:44Z","timestamp":1777508984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":51,"alternative-id":["S0223523426002837"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118838","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of APO-50815, a potent WEE1 kinase inhibitor with exceptional efficacy against patient-derived colorectal cancer organoids","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118838"}}